2026-09-19T14:41:04Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/844062026-06-16T18:17:11Zcom_1721.1_7582com_1721.1_7581col_1721.1_131022
Jeffrey M. Karp.
Ankrum, James Allen
Harvard--MIT Program in Health Sciences and Technology.
Harvard University--MIT Division of Health Sciences and Technology
2014-01-23T18:42:01Z
2014-01-23T18:42:01Z
2013
http://hdl.handle.net/1721.1/84406
868019053
Thesis (Ph. D. in Medical Engineering)--Harvard-MIT Program in Health Sciences and Technology, 2013.
Cataloged from PDF version of thesis. Vita.
Includes bibliographical references.
Cell-based therapies, which rely on transplanted cells to restore function to damaged tissues, are currently under investigation in clinical trials. Stem and progenitor cells, including mesenchymal stem cells (MSCs), have shown potential in pre-clinical models to treat diseases ranging from connective tissue defects, through differentiating into bone or cartilage forming cells, to inflammatory conditions, through suppressing activated immune cells. While the ability of stem cells to differentiate into multiple lineages, secrete trophic factors, and modulate inflammatory processes has made them applicable to many diseases, these diverse functions also pose challenges in controlling their phenotype. In this thesis a new platform technology to influence the phenotype of cells is described and used to solve three critical challenges in MSCbased therapies, controlling MSC differentiation, tracking cells, and enhancing MSC's immunomodulatory potency. MSCs were found to efficiently and stably internalize micron-sized biodegradable particles. The platform can be tuned to specific applications through incorporation of phenotype altering drugs or other payloads into particles. In the first study, particles were loaded with a small molecule drug, dexamethasone (DEX), that induces MSC osteogenic differentiation. Modification of MSCs with DEX-particles resulted in differentiation of particle-laden cells to the same extent as those grown in osteogenic media. Furthermore, DEX was released from the cells in sufficient quantities to influence neighboring and distant cells demonstrating the particle platform can influence both the modified cell and its microenvironment. Next, the platform was adapted to address the need for longitudinal tracking of MSCs. Loading iron oxide nanoparticles in the microparticles resulted in enhanced tracking of MSCs by MRI from 6 days with nanoparticles alone to beyond 12 days with iron oxide microparticles. Finally, the novel discovery that glucocorticoid steroids significantly increase the immunomodulatory potency of MSCs by up-regulating expression of indoleamine-2,3- dioxygenase (IDO) is reported. Loading MSCs with particles containing the glucocorticoid steroid, budesonide, doubled their potency in suppressing activated peripheral blood mononuclear cell co-cultures in an IDO dependent manner. While the platform presented here was used to control, track, and augment MSCs, it can easily be tailored to control the function of other therapeutically relevant cells to develop next-generation cell-based therapies.
by James Allen Ankrum.
Ph.D. in Medical Engineering
203 pages
eng
Massachusetts Institute of Technology
M.I.T. theses are protected by
copyright. They may be viewed from this source for any purpose, but
reproduction or distribution in any format is prohibited without written
permission. See provided URL for inquiries about permission.
http://dspace.mit.edu/handle/1721.1/7582
Harvard--MIT Program in Health Sciences and Technology.
A microparticle engineering approach to enhance the potency of mesenchymal stem cells
Thesis
application/pdf
false
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="93c16e04-8a85-4fed-bde7-371cdb19869f">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Language>eng</Language>
<Title>A microparticle engineering approach to enhance the potency of mesenchymal stem cells</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2013</PublicationDate>
<Authors>
<Author>
<DisplayName>Ankrum, James Allen</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://dspace.mit.edu/handle/1721.1/7582</License>
<Keyword>Harvard--MIT Program in Health Sciences and Technology.</Keyword>
<Abstract>Cell-based therapies, which rely on transplanted cells to restore function to damaged tissues, are currently under investigation in clinical trials. Stem and progenitor cells, including mesenchymal stem cells (MSCs), have shown potential in pre-clinical models to treat diseases ranging from connective tissue defects, through differentiating into bone or cartilage forming cells, to inflammatory conditions, through suppressing activated immune cells. While the ability of stem cells to differentiate into multiple lineages, secrete trophic factors, and modulate inflammatory processes has made them applicable to many diseases, these diverse functions also pose challenges in controlling their phenotype. In this thesis a new platform technology to influence the phenotype of cells is described and used to solve three critical challenges in MSCbased therapies, controlling MSC differentiation, tracking cells, and enhancing MSC's immunomodulatory potency. MSCs were found to efficiently and stably internalize micron-sized biodegradable particles. The platform can be tuned to specific applications through incorporation of phenotype altering drugs or other payloads into particles. In the first study, particles were loaded with a small molecule drug, dexamethasone (DEX), that induces MSC osteogenic differentiation. Modification of MSCs with DEX-particles resulted in differentiation of particle-laden cells to the same extent as those grown in osteogenic media. Furthermore, DEX was released from the cells in sufficient quantities to influence neighboring and distant cells demonstrating the particle platform can influence both the modified cell and its microenvironment. Next, the platform was adapted to address the need for longitudinal tracking of MSCs. Loading iron oxide nanoparticles in the microparticles resulted in enhanced tracking of MSCs by MRI from 6 days with nanoparticles alone to beyond 12 days with iron oxide microparticles. Finally, the novel discovery that glucocorticoid steroids significantly increase the immunomodulatory potency of MSCs by up-regulating expression of indoleamine-2,3- dioxygenase (IDO) is reported. Loading MSCs with particles containing the glucocorticoid steroid, budesonide, doubled their potency in suppressing activated peripheral blood mononuclear cell co-cultures in an IDO dependent manner. While the platform presented here was used to control, track, and augment MSCs, it can easily be tailored to control the function of other therapeutically relevant cells to develop next-generation cell-based therapies.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>